These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32815678)

  • 21. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.
    Pearce G; Ryan PF; Delmas PD; Tabensky DA; Seeman E
    Br J Rheumatol; 1998 Mar; 37(3):292-9. PubMed ID: 9566670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Glucocorticoid-induced osteoporosis and bone mineral densimetry].
    Tanaka I; Oshima H
    Clin Calcium; 2004 Dec; 14(12):77-82. PubMed ID: 15577178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone safety of low-dose glucocorticoids in rheumatic diseases.
    Saag KG
    Ann N Y Acad Sci; 2014 May; 1318():55-64. PubMed ID: 24815076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
    Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone.
    Hattori K; Hirano Y; Kojima T
    Int J Rheum Dis; 2020 Nov; 23(11):1581-1586. PubMed ID: 32996694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy].
    Hatz HJ; Helmke K
    Z Rheumatol; 1992; 51(5):213-21. PubMed ID: 1476006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fracture Risk and Its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study.
    Nam B; Sung YK; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Cho SK
    J Korean Med Sci; 2021 Oct; 36(41):e263. PubMed ID: 34697929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.
    Owen CE; McMaster C; Liew DFL; Leung JL; Scott AM; Buchanan RRC
    Int J Rheum Dis; 2021 Jan; 24(1):56-62. PubMed ID: 33043616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice.
    Helliwell T; Hider SL; Mallen CD
    Br J Gen Pract; 2013 May; 63(610):e361-6. PubMed ID: 23643235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
    Soen S
    Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids.
    Mackie SL; Pease CT; Fukuba E; Harris E; Emery P; Hodgson R; Freeston J; McGonagle D
    Ann Rheum Dis; 2015 Dec; 74(12):2188-92. PubMed ID: 26376658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
    Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
    Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides-a cross-sectional analysis with dose-response analyses.
    Palmowski A; Akahoshi M; Muche B; Boyadzhieva Z; Hermann S; Terao C; Wiebe E; Buttgereit F
    Rheumatol Int; 2023 May; 43(5):903-909. PubMed ID: 36811660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service.
    Chantler IW; Davie MW; Evans SF; Rees JS
    Ann Rheum Dis; 2003 Apr; 62(4):350-2. PubMed ID: 12634236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study.
    Mazzantini M; Torre C; Miccoli M; Baggiani A; Talarico R; Bombardieri S; Di Munno O
    J Rheumatol; 2012 Mar; 39(3):552-7. PubMed ID: 22247343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
    Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
    Suzuki Y; Sato S
    Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.